Head and Neck Neoplasms Clinical Trial
Official title:
Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
This phase II trial studies the safety and effectiveness of an induction chemotherapy (ACF) consisting of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), cisplatin and fluorouracil followed by chemoradiation therapy in treating patients with stage III-IV squamous cell cancer of the head and neck. ACF may be an effective way to reduce or downgrade locally aggressive tumors, and improve the chance of eradication by chemoradiation.
Compared to the standard induction regimen of TPF (docetaxel, cisplatin, and 5-FU), the ACCF (nab-paclitaxel, cisplatin, cetuximab, and 5-FU) regimen included two therapeutic changes: nab-paclitaxel was substituted for docetaxel and cetuximab was added. The investigators propose to eliminate cetuximab from the ACCF regimen to isolate the treatment effects of nab-paclitaxel when given with cisplatin and 5-FU. The primary objective of the ACF proposal is to determine the complete (CR) rate by clinical examination at the primary tumor site following two cycles of ACF. An important secondary objective will be to compare the tumor response rates at the primary site following two cycles of ACF to our historical experience following two cycles of ACCF (protocol # ABX 218/HRPO# 08-0911). In addition, the investigators will compare adverse events (AEs) between patients who receive ACF to the historical group given ACCF. From these two comparisons, we aim to determine if either ACF or ACCF is superior based on a balance of efficacy (using the surrogate prognostic endpoint of CR rate at primary tumor site) and toxicity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05980598 -
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02548377 -
Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial
|
N/A | |
| Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06347185 -
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
|
N/A | |
| Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
| Terminated |
NCT02975739 -
Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors
|
N/A | |
| Recruiting |
NCT00982436 -
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01025518 -
DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT00248235 -
Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00135161 -
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
|
Phase 1 | |
| Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
| Not yet recruiting |
NCT06458517 -
Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers
|
N/A | |
| Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
| Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
| Terminated |
NCT03286972 -
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
|
||
| Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Recruiting |
NCT03975465 -
EMST and Swallowing in Long-Term Survivors of HNCA
|
N/A | |
| Recruiting |
NCT03678649 -
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
|
Phase 2 | |
| Completed |
NCT03292250 -
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
|
Phase 2 | |
| Completed |
NCT06446570 -
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
|
Phase 2 |